Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis

Tobias Tritschler MD, MSc1,2 | Anuj Patel BHSc2 | Noémie Kraaijpoel MD, PhD3 | Deepak L. Bhatt MD, MPH4 | Giuseppe De Luca MD5 | Pietro Di Santo MD, MSc6 | Fausto Feres MD7 | Ricardo A. Costa MD7 | Benjamin Hibbert MD, PhD6 | Takaaki Isshiki MD8 | Grégoire Le Gal MD, PhD2 | Lana A. Castellucci MD, MSc2

1Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
3Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
4Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, Boston, Massachusetts, USA
5Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy
6University of Ottawa Heart Institute, Ottawa, Ontario, Canada
7Department of Invasive Cardiology, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
8Division of Cardiology, Teikyo University Hospital, Tokyo, Japan

Abstract

Background: Assessment of the case-fatality rate (CFR) of major bleeding on dual antiplatelet therapy (DAPT) may improve balancing risks and benefits of different durations of DAPT following percutaneous coronary intervention (PCI).

Objectives: To determine the CFR of major bleeding in patients on DAPT after PCI and to compare rates among different durations of DAPT.

Methods: Medline, Embase, and CENTRAL were searched from inception to August 2021 for randomized trials that reported fatal bleeding among patients who were randomized to ≥1 month of DAPT following PCI. Summary estimates for CFRs of major bleeding were calculated using the random-effects inverse-variance method. Statistical heterogeneity was evaluated using the I² statistic.

Results: Of 2777 citations obtained by the search, 15 (48%) of 31 potentially eligible studies were excluded because fatal bleeding was not reported, leaving 16 studies that were included in the analysis. Overall, there were 823 major bleeding events including 91 fatal events in 48,884 patients who were assigned to receive DAPT during study follow-up. The CFR of major bleeding was 10.8% (95% confidence interval [CI], 7.1–16.2; I² = 50%) in the entire study population, and 13.8% (95% CI, 6.5–27.1; I² = 28%), 11.2% (95% CI, 6.7–18.0; I² = 0%), and 5.8% (95% CI, 3.0–11.1; I² = 0%) in
Deciding on the optimal duration of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y₁₂ receptor inhibitor after implantation of drug-eluting stents (DES) in patients with coronary artery disease is challenging. Extending DAPT beyond the standard 12-month duration decreases the risk of major cardiovascular events but increases the risk of bleeding. Although the benefit in terms of cardiovascular mortality, myocardial infarction, and revascularization was evaluated in several meta-analyses, the effect of different durations of DAPT on the risk of bleeding and its clinical consequences, in particular fatal events, have received less attention. Furthermore, evaluation of the safety of different durations of DAPT is hampered by heterogeneous bleeding definitions across studies.

Assessment of the case-fatality rate of major bleeding may help improve balancing risks and benefits of different durations of DAPT because not only the absolute risk of major bleeding but also its fatality should be considered when individualizing the duration of DAPT. The case-fatality rate also allows to measure the impact of bleeding events during different treatment periods, which may be important because a major bleed in the first months of DAPT may have different consequences compared with a major bleed after the initial 12 months of DAPT. Furthermore, the case-fatality rate of major bleeding provides an objective measure of bleeding severity, when comparing results among studies using different bleeding definitions.

In this systematic review and meta-analysis, we therefore aimed to determine the case-fatality rate of major bleeding events after percutaneous coronary intervention (PCI) with DES, to evaluate case-fatality rates across different durations of DAPT and bleeding definitions, and to compare the risk of fatal bleeding in patients receiving short-, standard-, and long-term DAPT.

1 | INTRODUCTION

2 | METHODS

2.1 | Literature search and eligibility criteria

Medline, Embase, and Cochrane Central Register of Controlled Trials were searched without language restriction from inception to August 11, 2021, for relevant studies combining terms for “randomized controlled trial,” “percutaneous coronary intervention,” “drug-eluting stent,” “dual antiplatelet therapy,” “aspirin,” “clopidogrel,” “prasugrel,” and “ticagrelor.” The search strategy (Table S1) was reviewed by an information specialist according to the guideline for Peer Review of Electronic Search Strategies. To identify additional studies, we consulted content experts and searched references of included studies.

Randomized controlled trials comparing different durations or agents of DAPT in DES-treated patients with coronary artery disease were eligible. Studies were included if they fulfilled the following three criteria: (1) the study prospectively enrolled patients with coronary artery disease who underwent implantation of DES; (2) participants were randomized to receive any combination of aspirin and a P2Y₁₂ receptor inhibitor (i.e., clopidogrel, prasugrel, or ticagrelor) for at least 1 month; and (3) fatal bleeding events were reported or provided by the study investigators. The protocol of this study was registered with PROSPERO (CRD42020193341). Ethical approval was not sought because this meta-analysis was based on already published study-level data.

2.2 | Study selection, data extraction, and risk of bias assessment

Two investigators independently screened titles, abstracts, and subsequently full-text articles using Covidence systematic review software (www.covidence.org). Data extraction and assessment for risk of bias
were performed in duplicate by two investigators using the revised Cochrane Collaboration’s method for assessing risk of bias in randomized trials (RoB 2). Standardized forms were used to extract data including study and participant characteristics, definitions of major bleeding, and study outcomes. Disagreements at screening, data extraction, or risk of bias assessment were resolved through discussion or by consulting a third author. In case relevant information in an eligible study was not available, the principal investigator of the study was contacted to provide the data of interest. A reminder to share data was sent 3 weeks after the initial invitation to collaborate. If the author did not respond, the study was excluded before performing the analysis in August 2021.

2.3 Study outcomes

The primary study outcome was fatal bleeding. Bleeding events were classified as “major bleeding” based on the primary bleeding definition of the individual studies (Table S2). The case-fatality rate of major bleeding was defined as the proportion of fatal bleeding events relative to the total number of major bleeding events.

We specified secondary outcomes in the study protocol but decided to omit meta-analyses on these outcomes, because our systematic review did not identify more data than already meta-analyzed in previous studies.1,5

2.4 Statistical analysis

Duration of DAPT was categorized as short term (i.e., ≤6 months), standard term (i.e., 12 months), and long term (i.e., >12 months). Summary estimates (i.e., proportion for case-fatality rates and risk ratios for treatment comparisons) were calculated using the random effects inverse-variance method. A continuity correction of 0.5 was used in studies with zero cell frequencies. The Sidik-Jonkman estimator for between-study variance and the method by Hartung and Knapp were used to adjust test statistics and confidence intervals for treatment comparisons.6 For the calculation of case-fatality rates, a logit transformation was conducted before pooling proportions and the Wilson score method was used to calculate 95% confidence intervals (CIs).

Patients who were assigned to DAPT during the study follow-up were considered in the analysis of case-fatality rates; those on antiplatelet monotherapy were excluded. For example, if a study randomized patients 12 months after DES insertion to aspirin monotherapy versus DAPT, only patients assigned to the DAPT arm were considered for the analysis of case-fatality rates. Study arms and follow-up periods that were considered for the analysis of case-fatality rates of major bleeding are depicted in Figure 1.

Subgroup analyses were performed by primary bleeding definition, duration of DAPT, and type of P2Y₁₂ receptor inhibitor (i.e., studies or study arms in which >90% of patients received clopidogrel vs. heterogenous use of P2Y₁₂ receptor inhibitors vs. use of prasugrel or ticagrelor in all patients). For the estimation of case-fatality rates by duration of DAPT, only studies reporting events for a specific DAPT period were considered (i.e., first 12 months vs. beyond 12 months after DES insertion). For example, the long-term DAPT arm of the PRODIGY study was not included for the estimation of the case-fatality rate of major bleeding on long-term DAPT because the study only reported bleeding events for the entire period of months 2-24 after DES insertion (Figure 1).

In sensitivity analyses, we excluded trials at high risk of bias and studies or study arms in which P2Y₁₂ inhibitors other than clopidogrel were used for DAPT in ≥10% of patients.

Statistical heterogeneity was evaluated using the I² statistic and by providing 95% prediction intervals.24 Small-study bias was evaluated using the Egger regression test. A p value <.05 was considered to indicate statistical significance. All analysis were performed in R, version 3.6.3, using the meta package for meta-analysis.5

3 RESULTS

Of the 2777 citations identified from the systematic literature search, 175 studies were assessed as full texts and 31 considered potentially relevant (Figure S1; Table S3). Fatal bleeding was reported in the primary publication of 15 (48%) potentially relevant studies.10–24 After contacting corresponding authors for unreported data on fatal bleeds, a total of 16 studies were included in the review,10–25 whereas the remaining 15 studies were excluded because information required for our analysis was unavailable or not provided (Table S3). All excluded studies assessed bleeding as their primary safety outcome but did not report the number of fatal bleeding events in the primary trial publication or secondary publications identified by our search (Table S3).

3.1 Characteristics of included studies and bias assessment

The 16 included studies enrolled a total of 62,648 patients. Mean age ranged from 59 to 69 years (median 64 years); 16,985 (27%) were female. Among the 16 studies included in the analysis, two (n = 3352) compared different P2Y₁₂ receptor inhibitors,10,11 seven (n = 33,668) evaluated short-term versus standard-term DAPT,12-17,25 five (n = 20,351) long-term versus standard-term DAPT,18-22 and two (n = 5277) short-term vs long-term DAPT23,24 (Figure 1; Table 1). Most patients (57% [27,983/48,884]) who were allocated to DAPT during study follow-up received aspirin plus clopidogrel (Table 1). In the GLOBAL LEADERS study,12 all patients on short-term DAPT and 4146 (52%) on standard-term DAPT received ticagrelor; in the TICO study,17 all patients on DAPT received ticagrelor. The PRASFIT-Elective study randomized patients to prasugrel plus aspirin (n = 370) or clopidogrel plus aspirin for 6 months (n = 372).10 The TROPICAL ACS study randomized patients to aspirin plus prasugrel (n = 1306) or aspirin plus desescalation from prasugrel to clopidogrel based on platelet function testing 14 days after hospital discharge (798 received clopidogrel [61%] and 506
3.2 | Fatal bleeding

A total of 98 (0.2%) fatal bleeds occurred in 59,296 patients who were included in the 14 studies that evaluated different durations of DAPT, and one (0.03%) fatal bleed occurred in 3352 patients who were included in the two studies evaluating different P2Y$_{12}$ receptor inhibitors. Of the studies evaluating different DAPT durations, 12 studies assessed either short- or extended-term DAPT versus standard-term DAPT ($n = 54,019$; fatal bleeds, 82 [0.2%]). Compared with patients allocated to standard-term DAPT, the risk of fatal bleeding did not differ in those allocated to long-term DAPT (risk ratio, 1.09; 95% CI, 0.35–3.42; $I^2 = 0$%; 95% prediction interval, 0.09–13.3; Figure S2) or short-term DAPT (risk ratio, 0.70; 95% CI, 0.36–1.39; $I^2 = 0$%; 95% prediction interval, 0.19–2.57; Figure S3).

3.3 | Case-fatality rate of major bleeding

A total of 823 major bleeds including 91 fatal events occurred in 48,884 patients who were assigned to receive short-term, standard-term, or long-term DAPT during the follow-up period. The overall case-fatality rate of major bleeding was 10.8% (95% CI, 7.1–16.2; $I^2 = 50$%);
| Study (first author, year) | Funding source | Design | Setting | DAPT duration | Use of clopidogrel for DAPT | Time point of randomization | Follow-up duration after randomization | Major bleeding definition |
|---------------------------|----------------|--------|---------|---------------|----------------------------|----------------------------|--------------------------------------|-------------------------------|
| 1-Month DAPT (Hong, 2021)³⁴ | Industrial | Randomized, open-label, noninferiority trial | Multicenter Asia | 1 month \(n = 1507\); 6–12 months \(n = 1513\) | 1405/1507 (93%); 1421/1513 (94%) | At DES insertion | 12 month | STEEPLE major bleed |
| ARCTIC- Interruption (Collet, 2014)³⁵ | Industrial and nonindustrial | Randomized, open-label, superiority trial | Multicenter Europe | 12 month \(n = 624\); 18–30 months \(n = 635\) | NA; 569/635 (90%) | 12 month after DES insertion | Median of 17 month | STEEPLE major bleed |
| DAPT (Mauri, 2014)³⁶ | Industrial and nonindustrial | Randomized, double-blind, superiority trial | Multicenter worldwide | 12 month \(n = 4941\); 30 month \(n = 5020\) | NA; 3275/5020 (65%) | 12 month after DES insertion | 18 month | GUSTO severe or moderate |
| DES-LATE (Lee, 2014)³⁷ | Nonindustrial | Randomized, open-label, superiority trial | Multicenter Asia | 12 month \(n = 2514\); 36 months \(n = 2531\) | NA; 2531/2531 (100%) | 12–18 months after DES | 24 month | TIMI major bleed |
| GLOBAL LEADERS (Vanckx, 2018)³⁸ | Industrial | Randomized, open-label, superiority trial | Multicenter worldwide | 1 month \(n = 7980\); 12 month \(n = 7988\) | 0/7980 (0%); 3842/7988 (48%) | At DES insertion | 24 month | BARC 3 or 5 |
| ISAR-SAFE (Schulz-Schupke, 2015)³⁹ | Industrial and nonindustrial | Randomized, double-blind, noninferiority trial | Multicenter worldwide | 6 month \(n = 1997\); 12 month \(n = 2003\) | NA; 2003/2003 (100%) | 6 month after DES insertion | 9 month | TIMI major bleed |
| NIPPON (Nakamura, 2017)⁴⁰ | Industrial and nonindustrial | Randomized, open-label, noninferiority trial | Multicenter Asia | 6 month \(n = 1654\); 18 month \(n = 1653\) | 1619/1654 (98%); 1605/1653 (97%) | At DES insertion | Median of 435d | Modified REPLACE-2 major bleed |
| OPTIDUAL (Helft, 2016)⁴¹ | Industrial and nonindustrial | Randomized, open-label, superiority trial | Multicenter Europe | 12 month \(n = 690\); 48 month \(n = 695\) | NA; 695/695 (100%) | 12 month after DES insertion | 36 month | ISTH major bleed |
| OPTIMIZE (Feres, 2013)⁴² | Industrial | Randomized, open-label, noninferiority trial | Multicenter South America | 3 month \(n = 1563\); 12 month \(n = 1556\) | 1563/1563 (100%); 1556/1556 (100%) | At DES insertion | 12 month | Modified REPLACE-2 major bleed |
| PRASFIT-Elective (Ishihaki, 2014)⁴³ | Industrial | Randomized, double-blind trial | Multicenter Asia | 6 month \(n = 370\); 6 month \(n = 372\) | 0/370 (0%); 372/372 (100%) | At DES insertion | 6 month | TIMI major bleed |
| PRODIGY (Valgimigli, 2012)⁴⁴ | Nonindustrial | Randomized, open-label, superiority trial | Multicenter Europe | 6 month \(n = 983\); 24 month \(n = 987\) | 983/983 (100%); 987/987 (100%) | 1 month after insertion | 24 month | BARC 3 or 5 |
| REAL-ZEST-LATE (Park, 2010)⁴⁵ | Nonindustrial | Randomized, open-label, superiority trial | Multicenter Asia | 12 month \(n = 1344\); 33 month \(n = 1357\) | NA; 1357/1357 (100%) | 12 month after DES insertion | Median of 19 month | TIMI major bleed |
| REDUCE (De Luca, 2019)⁴⁶ | Industrial | Randomized, open-label, noninferiority trial | Multicenter Europe and Asia | 3 month \(n = 751\); 12 month \(n = 745\) | 306/751 (41%); 301/745 (40%) | At DES insertion | 24 month | BARC 3 or 5 |
| STOPDAPT-2 (Watanabe, 2019)⁴⁷ | Industrial | Randomized, open-label, noninferiority trial | Multicenter Asia | 1 month \(n = 1500\); 12 month \(n = 1509\) | 903/1500 (60%); 1509/1509 (100%) | At DES insertion | 12 month | TIMI major bleed |
| TICO (Kim, 2020)⁴⁸ | Industrial | Randomized, open-label, superiority trial | Multicenter Asia | 3 month \(n = 1527\); 12 month \(n = 1529\) | 0/1527 (0%); 0/1529 (0%) | At DES insertion | 12 month | TIMI major bleed |
| TROPICAL ACS (Sibbing, 2017)⁴⁹ | Industrial and nonindustrial | Randomized, open-label, noninferiority trial | Multicenter Europe | 12 month \(n = 1306\); 12 month \(n = 1304\) | 0/1306 (0%); 798/1304 (61%) | At DES insertion | 12 month | BARC 3 or 5 |

Abbreviations: DAPT, dual antiplatelet therapy; DES, drug-eluting stent; NA, not applicable.

*Major bleeding was defined as BARC 2, 3, or 5 bleeds in the original trial. For this meta-analysis, only BARC 3 or 5 bleeds were considered to be a major bleed.
TRITSCHLER et al.

95% prediction interval, 2.7–34.0; Figure 2). The case-fatality rate of major bleeding in patients on short-term DAPT (n = 16,553), standard-term DAPT (n = 19,453), and long-term DAPT (n = 10,238) was 13.8% (95% CI, 6.5–27.1; I² = 28%), 11.2% (95% CI, 6.7–18.0; I² = 0%), and 5.8% (95% CI, 3.0–11.1; I² = 0%), respectively (Figure 3; p = 0.63 and p = 0.12 for subgroup difference between short- and standard-term DAPT and between standard- and long-term DAPT, respectively).

Six different major bleeding definitions were used across the 16 included studies (Table 1). The case-fatality rate of major bleeding did not differ statistically significantly across bleeding definitions, but few studies constituted each subgroup (Figure 4).

The case-fatality rates of major bleeding did not differ according to the type of P2Y₁₂ receptor inhibitor (Figure S4).

Small-study bias was not evident for case-fatality rates of major bleeding (Egger test, p = .16). However, reporting bias cannot be excluded, because fatal bleeding was not reported in 48% of potentially relevant studies.

3.4 | Sensitivity analysis

When studies at high risk of bias or those using a P2Y₁₂ inhibitor other than clopidogrel in ≥10% of patients were excluded in sensitivity analyses, the overall case-fatality rate of major bleeding, as well as the subgroup estimates did not change meaningfully (Figures S5–S10).

4 | DISCUSSION

Our meta-analysis of 16 studies demonstrates that the case-fatality rate of major bleeding is substantial (10.8%). It may be especially high in the first 12 months of DAPT (13.8% for short-term DAPT and 11.2% for standard-term DAPT) and decrease during long-term DAPT (5.8%). Whether the case-fatality rate of major bleeding varies across different bleeding definitions remains uncertain, mainly because of the numerous definitions that were used with subsequently low events per subgroup. Our findings suggest that future studies should assess whether the case-fatality rate of major bleeding should be considered in the risk–benefit equation for different DAPT durations and be used by clinicians to improve individualized management of patients who undergo PCI, when combined with cardiovascular mortality and major bleeding rates. Furthermore, fatal bleeding was underreported, and reporting of such events should be encouraged in future research on DAPT to allow assessment of treatment effects on the most severe form of bleeding.

The consequences of major bleeding have received little attention in previous meta-analysis of DAPT following PCI. In an individual participant data meta-analysis of randomized controlled trials evaluating DAPT for miscellaneous indications (i.e., acute coronary syndrome, high risk of cardiovascular disease, lacunar stroke, atrial fibrillation, PCI), patients on DAPT had an increased risk of fatal bleeding compared with those who received aspirin plus placebo (hazard ratio, 1.42; 95% CI, 1.04–1.95). In contrast, a meta-analysis of 33,435 patients with previous myocardial infarction showed that long-term DAPT, compared with standard-term DAPT, was not associated with an increased risk of fatal bleeding (risk ratio 0.91; 95% CI, 0.53–1.58), but a higher risk of major bleeding (risk ratio, 1.73; 95% CI, 1.19–2.50). Our study of DES-treated patients supports findings that long-term DAPT, compared with standard-term DAPT, is not associated with an increased risk of fatal bleeding (risk ratio, 1.09; 95% CI, 0.35–3.42) in DES-treated patients with coronary artery disease. However, our and other studies are underpowered to adequately assess differences of this rare outcome, despite evaluating data of close to 60,000 patients. Similarly, previous meta-analyses failed to show differences in cardiovascular...
death rates between different durations of DAPT,1,5 and the effect of different DAPT durations on all-cause mortality is uncertain.1,5 As such, comparing rates of cardiovascular and major bleeding events and differentially weigh these surrogate outcomes of death by using case-fatality rates may help estimating mortality differences between different durations of DAPT. In this regard, our study provides important additional information. The overall case-fatality rate of major bleeding in patients on DAPT was substantial and with 10.8% comparable to the case-fatality rate of major bleeding in patients on direct oral anticoagulants (8%-10%) or vitamin K antagonists (8%-11%).28,29 This risk is important to consider when counseling patients on safety measures to reduce the risk of bleeding (e.g., avoid contact sports, wearing helmets) and when evaluating the indication for a proton pump inhibitor. Furthermore, the case-fatality rates may be lower during long-term DAPT than in the first 12 months of DAPT following PCI. Similarly, in some randomized controlled trials evaluating DAPT in patients with clinically evident cardiovascular disease, the bleeding excess for DAPT versus antiplatelet monotherapy was confined to the first year,30-32 whereas in other trials it was not.18,23 Combined with our results, these findings may indicate that patients who are going to bleed on DAPT tend to bleed early and that the risk of such a bleed to be fatal may be more pronounced in the first 12 months. Patients who do not experience a bleeding event that led to cessation of treatment during the first 12 months (so-called stress test)33 and continued DAPT beyond 12 months may have a lower risk of adverse bleeding outcomes. This hypothesis may particularly apply to patients who experience an extracranial bleeding event because occurrence of intracranial hemorrhage is more stochastic.34

Heterogeneous bleeding definitions limit between-study comparisons and meta-analysis of different DAPT durations. Importantly, there is more than fourfold difference in the frequency of major bleeding events across different definitions,35 and, as such, bleeding definitions influence the assessment of the net clinical benefit and decisions regarding the optimal duration of DAPT in clinical practice. Although our analysis was underpowered to detect a statistically significant difference in case-fatality rates of major bleeding according to bleeding definitions, point estimates of case-fatality

| Study (Author, Year) | Events | Total | Case-fatality rate | 95% CI | Weight |
|----------------------|--------|-------|--------------------|-------|--------|
| Short-term DAPT (≤6 months) | | | | | |
| 1-Month DAPT (Hong, 2021) [short] | 1 | 26 | 0.04 [0.01; 0.19] | 3.2% |
| GLOBAL LEADERS (Vranckx, 2018) [short] | 22 | 163 | 0.13 [0.09; 0.20] | 10.7% |
| OPTIMIZE (Feres, 2013) [short] | 3 | 10 | 0.30 [0.11; 0.60] | 5.4% |
| PRASFIT-Selective (Ishikawa, 2014) | 8 | 0 | 0.00 [0.00; 0.32] | 1.8% |
| PRODIGY (Valgimigli, 2012) [short] | 5 | 19 | 0.26 [0.12; 0.49] | 7.1% |
| REDUCE (De Luca, 2019) [short] | 1 | 10 | 0.10 [0.02; 0.40] | 3.1% |
| STOP-DAPT2 (Watanabe, 2019) [short] | 1 | 3 | 0.33 [0.06; 0.79] | 2.5% |
| TICO (Kim, 2020) [short] | 0 | 25 | 0.00 [0.00; 0.13] | 1.9% |
| Random effects model | 264 | | 0.14 [0.07; 0.27] | 35.8% |
| Heterogeneity: $i^2 = 28\%$, $R^2 = 0.7076$, $p = 0.20$ |

| Standard-term DAPT (12 months) | | | | | |
| 1-Month DAPT (Hong, 2021) [standard] | 3 | 38 | 0.08 [0.03; 0.21] | 6.2% |
| GLOBAL LEADERS (Vranckx, 2018) [standard] | 24 | 169 | 0.14 [0.10; 0.20] | 10.8% |
| ISAR-SAFE (Schulz-Schupke, 2015) | 1 | 5 | 0.20 [0.04; 0.62] | 2.8% |
| OPTIMIZE (Feres, 2013) [standard] | 2 | 14 | 0.14 [0.04; 0.40] | 4.8% |
| REDUCE (De Luca, 2019) [standard] | 2 | 12 | 0.17 [0.05; 0.45] | 4.7% |
| STOP-DAPT2 (Watanabe, 2019) [standard] | 3 | 16 | 0.19 [0.07; 0.43] | 5.9% |
| TICO (Kim, 2020) [standard] | 2 | 45 | 0.04 [0.01; 0.15] | 5.1% |
| TROPICAL ACS (Sibbing, 2017) [prasugrel] | 1 | 20 | 0.05 [0.01; 0.24] | 3.2% |
| TROPICAL ACS (Sibbing, 2017) [de-escalation] | 0 | 17 | 0.00 [0.00; 0.18] | 1.9% |
| Random effects model | 336 | | 0.11 [0.07; 0.18] | 45.5% |
| Heterogeneity: $i^2 = 0\%$, $R^2 = 0.2382$, $p = 0.56$ |

| Long-term DAPT (>12 months) | | | | | |
| ARCTIC (Collet, 2014) | 0 | 7 | 0.00 [0.00; 0.35] | 1.8% |
| DAPT (Mauri, 2014) | 7 | 119 | 0.06 [0.03; 0.12] | 8.7% |
| DES-LATE (Lee, 2014) | 1 | 34 | 0.03 [0.01; 0.15] | 3.3% |
| OPTIDUAL (Hefti, 2016) | 1 | 14 | 0.07 [0.01; 0.31] | 3.2% |
| REAL-ZEST-LATE (Park, 2010) | 0 | 3 | 0.00 [0.00; 0.56] | 1.7% |
| Random effects model | 177 | | 0.06 [0.03; 0.11] | 18.7% |
| Heterogeneity: $i^2 = 0\%$, $R^2 = 0.0438$, $p = 0.93$ |

| Random effects model | 777 | | 0.11 [0.07; 0.16] | 100.0% |
| Prediction interval | | | | [0.03; 0.32] |
| Heterogeneity: $i^2 = 16\%$, $R^2 = 0.3755$, $p = 0.25$ |

Test for subgroup differences: $\chi^2 = 3.60$, df = 2 ($p = 0.17$)
rates ranged from 0% to 26%, highlighting the potential influence of different definitions on the fatality of bleeding events.

Following insertion of DES, the 2016 American College of Cardiology and American Heart Association guidelines recommend at least 6 months of DAPT in patients with stable ischemic heart disease and at least 12 months of DAPT in patients with acute coronary syndromes. The guidelines provide conditional recommendations for short-term DAPT and long-term DAPT depending on bleeding risk, which is determined based on clinical parameters (e.g., prior bleeding on DAPT, oral anticoagulant use). A recent individual patient-data meta-analysis, including 14,963 patients from eight randomized controlled trials, supports the approach to guide duration of DAPT based on the risk of bleeding. Our results indicate that not only the risk of major bleeding, but also its case-fatality rate should be considered in the risk-benefit equation in future studies because it may help estimating mortality differences, when combined with cardiovascular mortality rates, and because case-fatality rates may differ based on the duration of DAPT.

There are potential limitations to this study. First, 15 of 31 (48%) potentially relevant studies did not report fatal bleeding events. Second, we pooled trials with heterogeneous populations.

| Study (Author, Year)       | Events | Total | Case-fatality rate | 95% CI  | Weight |
|---------------------------|--------|-------|--------------------|--------|--------|
| STEEPLE                   |        |       |                    |        |        |
| 1-Month DAPT (Hong, 2021) | 4      | 64    | 0.06 [0.02; 0.15]  | 8.4%   |        |
| ARCTIC (Collet, 2014)     | 0      | 7     | 0.00 [0.00; 0.35]  | 2.2%   |        |
| Random effects model      | 71     |       | 0.06 [0.03; 0.15]  | 10.6%  |        |
| Heterogeneity: $I^2 = 0\%, \tau^2 = 0, p = 1.00$ |        |       |                    |        |        |
| GUSTO                     |        |       |                    |        |        |
| DAPT (Mauri, 2014)        | 7      | 119   | 0.06 [0.03; 0.12]  | 10.2%  |        |
| Random effects model      | 119    |       | 0.06 [0.03; 0.12]  | 10.2%  |        |
| Heterogeneity: not applicable |        |       |                    |        |        |
| TIMI                      |        |       |                    |        |        |
| TICO (Kim, 2020)          | 2      | 70    | 0.03 [0.01; 0.10]  | 6.1%   |        |
| DES-LATE (Lee, 2014)      | 1      | 34    | 0.03 [0.01; 0.15]  | 3.9%   |        |
| PRASFIT-Elective (Isshiki, 2014) | 0 | 8 | 0.00 [0.00; 0.32]  | 2.2%   |        |
| REAL-ZEST-LATE (Park, 2010) | 0 | 3 | 0.00 [0.00; 0.56]  | 2.1%   |        |
| ISAR-SAFE (Schulz-Schupke, 2015) | 1 | 5 | 0.20 [0.04; 0.62]  | 3.4%   |        |
| STOP-DAPT2 (Watanabe, 2019) | 4 | 19 | 0.21 [0.09; 0.43]  | 7.8%   |        |
| Random effects model      | 139    |       | 0.08 [0.03; 0.20]  | 25.6%  |        |
| Heterogeneity: $I^2 = 39\%, \tau^2 = 0.5391, p = 0.15$ |        |       |                    |        |        |
| BARC                      |        |       |                    |        |        |
| TROPICAL ACS (Sibbing, 2017) | 1  | 37  | 0.03 [0.00; 0.14]  | 3.9%   |        |
| REDUCE (De Luca, 2019)    | 3      | 22    | 0.14 [0.05; 0.33]  | 7.1%   |        |
| GLOBAL LEADERS (Vranckx, 2018) | 46 | 332 | 0.14 [0.11; 0.18]  | 13.2%  |        |
| PRODIGY (Valgimigli, 2012) | 14  | 53    | 0.26 [0.16; 0.40]  | 11.3%  |        |
| Random effects model      | 444    |       | 0.14 [0.06; 0.29]  | 35.6%  |        |
| Heterogeneity: $I^2 = 66\%, \tau^2 = 0.6646, p = 0.03$ |        |       |                    |        |        |
| modified REPLACE-2        |        |       |                    |        |        |
| NIPPON (Nakamura, 2017)   | 2      | 12    | 0.17 [0.05; 0.45]  | 5.6%   |        |
| OPTIMIZE (Feres, 2013)    | 5      | 24    | 0.21 [0.09; 0.40]  | 8.6%   |        |
| Random effects model      | 36     |       | 0.20 [0.10; 0.36]  | 14.2%  |        |
| Heterogeneity: $I^2 = 0\%, \tau^2 = 0.0016, p = 0.77$ |        |       |                    |        |        |
| ISTH                      |        |       |                    |        |        |
| OPTIDUAL (Helft, 2016)    | 1      | 14    | 0.07 [0.01; 0.31]  | 3.8%   |        |
| Random effects model      | 14     |       | 0.07 [0.01; 0.37]  | 3.8%   |        |
| Heterogeneity: not applicable |        |       |                    |        |        |
| Random effects model      | 823    |       | 0.11 [0.07; 0.16]  | 100.0% |        |
| Prediction interval       |        |       |                    |        |        |
| Heterogeneity: $I^2 = 50\%, \tau^2 = 0.4001, p = 0.01$ |        |       |                    |        |        |
| Test for subgroup differences: $\chi^2 = 7.50$, df = 5 ($p = 0.19$) | 0 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 |        | 0.03; 0.34 |

**FIGURE 4** Case-fatality rate of major bleeding by bleeding definition. CI, confidence interval.
that varied in study design, treatment strategy, and major bleeding definitions. To address heterogenous study designs, we considered only study arms that represent specific DAPT periods for the calculation of case-fatality rates (Figure 1). Furthermore, we performed subgroup and sensitivity analyses, which did not demonstrate meaningful differences in case-fatality rates by type of P2Y<sub>12</sub> receptor inhibitor or after exclusion of studies at high risk of bias. Overall, there was moderate statistical heterogeneity associated with the overall case-fatality rate of major bleeding ($I^2 = 50\%$; 95% prediction interval, 2.7%–34%), which could largely be explained by different durations of DAPT ($I^2 = 0\%$ for subgroups of standard-term and long-term DAPT; $I^2 = 28\%$ for subgroup of short-term DAPT). Third, inherent to the available data, different bleeding classifications were used to define major bleeding. Albeit our analysis did not suggest a statistically significant difference of case-fatality rates of major bleeding according to bleeding definitions, few studies constituted each subgroup which precludes a firm conclusion. Similarly, the subgroup analysis by duration of DAPT was underpowered and does not allow firm conclusions. Fourth, 13 (81%) studies used an open-label design, which may result in ascertainment and detection bias of bleeding events. However, most open-label trials used a central adjudication committee that was blinded to the treatment allocation of study participants and fatal bleeding is unlikely to be prone to these biases. Fifth, the introduction of reversal agents for ticagrelor may decrease case-fatality rates of major bleeding in the future. Sixth, the use of proton pump inhibitors may affect the risk of major bleeding on DAPT but the proportion of patients on a proton pump inhibitor during follow-up was rarely reported in the included studies, prohibiting a meaningful subgroup analysis by proton pump inhibitor use. Seventh, few studies provided data on race of the participants preventing the evaluation of differences in case-fatality rates by race. Finally, patients enrolled in trials that evaluate long-term DAPT might be at a lower risk of bleeding than those enrolled in trials evaluating shorter duration of DAPT. Whether this potential difference in the baseline risk of major bleeding affects the severity or consequences of a major bleeding event cannot be excluded. We did not request individual patient data, which would have allowed us to adjust estimates by various risk factors.

In conclusion, almost one-half of studies that evaluated DAPT after PCI did not report on fatal bleeding. The case-fatality rate of major bleeding on DAPT is substantial and may be higher in the first 12 months of DAPT than during long-term DAPT.

**AUTHOR CONTRIBUTIONS**

Study concept and design: T. T., N. K., G. L. G., and L. A. C. Study selection, data extraction, and assessment of risk of bias: T. T., A. P., and L. A. C. Data analysis: T. T. Drafting of the manuscript: T. T., N. K., and L. A. C. Critical revision of the manuscript for important intellectual content: All authors. Final approval of the manuscript: All authors. T. T. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**ACKNOWLEDGMENTS**

We thank Risa Shorr (information specialist at the Ottawa Hospital Research Institute) for reviewing the search strategy.

**FUNDING INFORMATION**

Drs. Tritschler, Le Gal, and Castellucci are members of the Canadian Venous Thromboembolism Research Network (ConVECTOR); the Network received grant funding from the Canadian Institutes of Health Research (funding reference: CDT-142654). Dr. Tritschler held an Early Postdoc.Mobility Award from the Swiss National Science Foundation (SNSF P2ZHP3_17799) and a Fellowship Award from the ConVECTOR Network. Dr. Le Gal holds a mid-career clinician scientist award from the Heart and Stroke Foundation of Ontario, and the Chair on the Diagnosis of Venous Thromboembolism, Department of Medicine, University of Ottawa. Dr. Castellucci holds a Heart and Stroke Foundation of Canada National New Investigator Award, and a Tier 2 research Chair in Thrombosis and Antiagulation Safety from the University of Ottawa. The funders had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, and in the decision to submit the article for publication.

**RELATIONSHIP DISCLOSURE**

Dr. Bhatt discloses the following relationships - Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, Plx Pharma, Regado Biosciences, Stasys; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair,
interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Affimune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Ceroo Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda. Dr. Hibbert reports funding as a clinical trial investigator from Abbott, Boston Scientific and Edwards Lifesciences outside of the submitted work. Dr. Ishikii has received patent royalties for medical devices from Nipro, and honoraria from Daiichi-Sankyo, Merck, Bristol-Meyers, Behring, Bayer, Abbott, Otsuka, Abiomed, Kowa and Novartis. Dr. Castellucci has received honoraria from Bayer, BMS-Pfizer Alliance, The Academy, LEO Pharma, Sanofi, and Servier. The remaining authors state that they have no conflicts of interest.

ORCID
Tobias Tritschler https://orcid.org/0000-0002-8775-0511
Noémie Kraaijpoel https://orcid.org/0000-0002-1124-695X
Deepak L. Bhatt https://orcid.org/0000-0002-1278-6245
Grégoire Le Gal https://orcid.org/0000-0002-9253-248X
Lana A. Castellucci https://orcid.org/0000-0003-1322-9368

TWITTER
Tobias Tritschler @TritschlerMD
Deepak L. Bhatt @DLBHATTMD
Pietro Di Santo @DiSantoPietro
Benjamin Hibbert @benhibbertMDPhD
Grégoire Le Gal @gregolegal
Lana A. Castellucci @LanaCastellucci

REFERENCES
1. Khan SU, Singh M, Valavoor S, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation. 2020;142:1425-1436.
2. Elliott J, Kelly SE, Bai Z, et al. Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: an umbrella review. Can J Cardiol. 2019;35:1039-1046.
3. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40-46.
4. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:k4898.
5. Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019;365:j2222.
6. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
7. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172:137-159.
8. IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6:e010247.
9. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153-160.
10. Iwashki T, Kimura T, Ogawa H, et al. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J. 2014;78:2926-2934.
11. Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747-1757.
12. Vranckx P, Valigianni M, Juni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940-949.
13. Schulz Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomised, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252-1263.
14. Hong SJ, Kim JS, Hong SJ, et al. 1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial. JACC Cardiovasc Interv. 2021;14:1801-1811.
15. De Luca G, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention. 2019;15:e990-e998.
16. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414-2427.
17. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. Jama. 2020;323:2407-2416.
18. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-2166.
19. Collet JP, Silvain J, Barthelemy D, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): a randomised trial. Lancet. 2014;384:1577-1585.
20. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304-312.
21. Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365–374.
22. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374-1382.
23. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-2026.
24. Nakamura M, Iijima R, Ako J, et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation. JACC Cardiovasc Interv. 2017;10:1189-1198.
25. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-2522.
26. Elmariah S, Doros G, Benavente OR, et al. Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis. Circ Cardiovasc Interv. 2018;11:e005795.
27. Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized controlled trials. Eur Heart J. 2016;37:390-399.
28. Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015;13:2012-2020.
29. Khan F, Tritschler T, Kimpton M, et al. Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis. Ann Intern Med. 2021;174:1420-1429.
30. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988.
31. Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Circulation. 2010;121:2575-2583.
32. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020;142:40-48.
33. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371:2134-2143.
34. Ha ACT, Bhatt DL, Rutka JT, Johnston SC, Mazer CD, Verma S. Intracranial hemorrhage during dual antiplatelet therapy: JACC review topic of the week. J Am Coll Cardiol. 2021;78:1372-1384.
35. Bergmark BA, Kamphuisen PW, Wiviott SD, et al. Comparison of events across bleeding scales in the ENGAGE AF-TIMI 48 trial. Circulation. 2019;140:1792-1801.
36. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Thorac Cardiovasc Surg. 2016;152:1243-1275.
37. Costa F, Van Klaveren D, Feres F, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019;73:741-754.
38. Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380:1825-1833.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Tritschler T, Patel A, Kraaijpoel N, et al. Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2022;6:e12834. doi: 10.1002/rth2.12834